The grant has been awarded by the Australian Government's National Health and Medical Research Council (NHMRC), and will be matched by the South Australian...
Expanded facility to manufacture mRNA-based therapies and vaccines Researchers at the University of Adelaide will address the design and manufacturi...
Recorded Q1'23 consolidated revenue of KRW 720.9 billion. Recorded Q1'23 consolidated operating profit of KRW 191.7 billion. Expected to main...
The mice model data indicates considerably shorter half life and accelerated onset while retaining generation-1 MDMA features. The objective of this effort...
"Receiving FDA approval on our HPAPI fill line is an exciting milestone for our company, and couldn't have happened without the hard work, hours of prepara...
Announced an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT045...
Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali" or "Cali Biosciences"), a biopharmaceutical company focused on the research and development o...
Recommended dose selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a study 23andMe Holding Co. (Nasdaq: M...
The project will see the site’s footprint increase by 32,000 square feet (3,000 square meters) to add capacity for the storage and handling of clinic...
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent c...
WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announces that it has added two 2,000 L reactors and a large-sca...
The newly acquired facility and team is in Bentley, a suburb of Perth in Western Australia. It will operate as a Contract Development and Manufacturing Org...
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for...
-Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced dosing of the first pati...
© 2025 Biopharma Boardroom. All Rights Reserved.
